Platinum-resistant Recurrent Ovarian Cancer Clinical Trial
Official title:
Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer: a Prospective, Single-arm, Open Label, Exploratory Phase 2 Clinical Trial.
The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in platinum-resistant recurrent ovarian cancer.
The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in platinum-resistant recurrent ovarian cancer.The patient has undergone surgery and received ≥2 lines of platinum-containing chemotherapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03642990 -
NR in Chemo-induced Peripheral Neuropathy
|
Phase 2 | |
| Recruiting |
NCT03699449 -
An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)
|
Phase 2 | |
| Active, not recruiting |
NCT04348032 -
Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06434610 -
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
|
Phase 2 | |
| Recruiting |
NCT05325229 -
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer
|
Phase 2 |